It is recommended that ADRUCIL Injection be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and who is well versed in the use of potent antimetabolites. Because of the possibility of severe toxic reactions, it is recommended that patients be hospitalized at least during the initial course of therapy.
These instructions should be thoroughly reviewed before administration of ADRUCIL.
ADRUCIL® Injection (fluorouracil injection, USP) an antineoplastic antimetabolite, is a colorless to faint yellow aqueous, sterile, nonpyrogenic injectable solution available in a 50 mL and 100 mL Pharmacy Bulk Package for intravenous administration.
ADRUCIL (FLUOROURACIL) is indicated for the following:
ADRUCIL Injection is effective in the palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas.
Media Articles Related to Adrucil (Fluorouracil)
New Standard of Care in Metastatic Pancreatic Cancer?
Source: Medscape Hematology-Oncology Headlines [2016.02.01]
Liposomal irinotecan combined with fluorouracil and leucovorin should be the standard of care for patients with metastatic pancreatic cancer that has progressed on gemcitabine, say researchers.
Medscape Medical News
Published Studies Related to Adrucil (Fluorouracil)
Irsogladine maleate reduces the incidence of fluorouracil-based
chemotherapy-induced oral mucositis. 
mucositis through a double-blind, placebo controlled trial... CONCLUSION: IM significantly reduced the incidence and maximum severity of oral
Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in
combination with salicylic acid treating actinic keratoses. 
practicability... CONCLUSIONS: Topical 0.5% 5-FU/SA demonstrated superior sustained clinical
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance
enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line
therapy for metastatic colorectal cancer. 
maintenance therapy for metastatic colorectal cancer (MCRC)... CONCLUSIONS: Enzastaurin combined with bevacizumab-based therapy is tolerable,
Comparison of the efficacy of intralesional triamcinolone acetonide and
5-fluorouracil tattooing for the treatment of keloids. 
for treatment of keloids... CONCLUSION: 5-FU tattooing was more effective than intralesional TAC for the
Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion. [2011.11.09]
BACKGROUND: The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT). This study evaluated the efficacy of combined 5-fluorouracil and pegylated interferon (PEG-IFN) alpha-2b in patients with advanced HCC... CONCLUSIONS: Although a prospective randomized controlled trial using a larger population of patients with advanced HCC is needed to evaluate combination therapy with 5-fluorouracil and PEG-IFNalpha-2b, this new combination therapy may be useful for patients with advanced HCC. Cancer 2011;. (c) 2011 American Cancer Society. Copyright (c) 2011 American Cancer Society.
Clinical Trials Related to Adrucil (Fluorouracil)
Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients [Enrolling by invitation]
The primary objective of this study is to evaluate whether the management of colorectal
cancer (CRC) patients with 5-fluorouracil (5-FU) exposure optimization testing reduces 5-FU
related toxicities and improves outcomes compared to the current standard of care. A
secondary objective is to characterize the variability of 5-FU levels among CRC patients
managed with 5-FU exposure optimization testing and the impact of such management on 5-FU
plasma levels and drug doses during the course of chemotherapy.
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients [Completed]
Phase I Objectives
1. The primary objective of this study is to determine the maximum tolerated dose (MTD) of
Docetaxel combined with 5-Fluorouracil and Oxaliplatin (D-FOX) in patients with untreated,
locally unresectable or metastatic adenocarcinoma of the stomach or gastroesophageal
1. To determine the qualitative and quantitative toxicity and reversibility of toxicity of
Phase II Objectives
1. To assess time to cancer progression to D-FOX treatment regimen.
1. To assess response rate to D-FOX treatment regimen.
2. To determine the qualitative and quantitative toxicity and reversibility of toxicity of
this combination treatment regimen.
3. Determine overall survival.
4. Perform an exploratory investigation into the effect of D-FOX on phenotypic
abnormalities in blood.
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab [Completed]
The goal of this clinical research study is to find the best combination of oxaliplatin,
bevacizumab, 5-fluorouracil, leucovorin, and cetuximab that can be given to patients with
advanced cancer that has spread to the liver. Different combinations of these drugs will be
used, and the safety of all drug combinations will also be studied.
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) [Active, not recruiting]
The goal of this clinical research study is to find the highest tolerable doses of the
combinations of lenalidomide and other drugs that can be given to patients with advanced
cancer. The safety of the drug combinations will also be studied.
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer [Terminated]
The purpose of this clinical trial is to determine whether the combination of 5-fluorouracil
(5-FU) plus a DAVANAT (carbohydrate polymer) along with Avastin and Leucovorin (LV) is
beneficial in treating colorectal cancer in patients unable to tolerate intensive
Page last updated: 2016-02-01